

The Urgency of Combating Secondary Bacterial Infection against the Background of Viral Infection

Aliev Shovkat Ruzimatovich ¹

Suyunova Charos Abdumo'min qizi ²

Abstract: Secondary infections frequently follow viral pulmonary illnesses, resulting in additional clinical difficulties and unfavorable disease outcomes. Secondary infection research is so crucial. Here, we examine clinical information on secondary bacterial infections that arise subsequent to the onset of lung viral infections. Children's morbidity and mortality are frequently caused by respiratory illnesses. When a toddler or infant has a respiratory tract infection and is feverish, medical professionals frequently face a difficult situation. Many medical professionals cite the difficulty in determining if the fever is brought on by a bacteria or a virus. This review's objective is to present the most recent data regarding bacterial infections caused by viruses. We discuss a number of in vitro and clinical investigations that corroborate the link between secondary bacterial infections and viruses. We also go into the pathophysiology and ways to prevent the cohabitation of bacteria and viruses. To find published literature about bacterial infections linked to respiratory viruses, the PubMed and MEDLINE databases were searched. Clinicians should have a thorough understanding of the variety of bacterial and viral coinfections or secondary infections that may manifest as viral respiratory disease thanks to this review. It is noteworthy how frequently serious bacterial infections and viral illnesses coexist. Preventing and treating viral diseases, particularly in young children, requires a similar focus. Healthcare professionals should also stress to parents the significance of clinical follow-up for newborns and young children with VRTI diagnoses. Furthermore, the use of MxA in the diagnosis of pediatric viral infections shows promise.

Keywords: Secondary infections, bacteria, infection, pulmonary illnesses, risk, virus.

¹ Associate Professor of the Department of Microbiology, Virology and Immunology

² Student of Tashkent State Medical University Faculty of Medical Prevention and Public Health, Group 204A, Tashkent, Uzbekistan

Introduction. Secondary infections frequently follow viral pulmonary illnesses, resulting in additional clinical difficulties and poor disease outcomes. Therefore, studying secondary infections is crucial. The clinical data of secondary bacterial infections that arise following lung viral infections are reviewed here. Children frequently get viral respiratory tract infections (VRTIs), which can range in severity from minor colds to potentially fatal infections. Since outbreaks of VRTIs are being related to an increased

occurrence of bacterial coinfections, the presence of a respiratory virus does not necessarily imply that the child has just a viral infection. Although the human body can typically eradicate respiratory viral infections without any aftereffects, occasionally viruses evade the immune response of the airways, potentially leading to serious respiratory illnesses. The lungs are shielded from external infections by strong mechanical and immunosuppressive mechanisms, although a single respiratory tract infection may alter immunity and pathology [1-5]. When a toddler or infant has a respiratory tract infection and is feverish, medical professionals frequently face a difficult situation. Many medical professionals cite the difficulty in determining if the fever is brought on by bacteria or viruses. In 20% to 60% of VRTI cases, acute otitis media (AOM) is a common bacterial coinfection. Additionally, the maxillary, ethmoidal, and frontal sinuses are altered in about 60% of children with VRTI. Furthermore, the influenza pandemic in 1918 was thought to have killed between 40 and 50 million people, many of whom had secondary bacterial pneumonia with *Streptococcus pneumoniae*. Although the exact mechanism underlying susceptibility to secondary infections is not well known, it is likely that opportunistic bacteria can colonize the host due to virus-mediated immunosuppression of the host innate immune system, as seen for *Streptococcus* [6-11]. Despite the fact that mammalian hosts are concurrently exposed to several (opportunistic) pathogens, the majority of research on host-pathogen interactions concentrates on a single-pathogen, one-host model. Viral-induced secondary bacterial infections are more common when the immune system reacts differently to one pathogen than to another infectious agent or agents. When a virus damages the mucosal layer, mammalian cells are more vulnerable to bacterial attachment and colonization; infections with respiratory syncytial virus (RSV), rhinovirus, and influenza virus cause bacterial adherence of *Streptococcus pneumoniae*, *Pseudomonas aeruginosa* and *Haemophilus influenzae*, as well as biofilm formation on the airway linings. *Staphylococcus aureus*, *S. pneumoniae*, *Neisseria meningitidis*, *H. influenzae*, *Klebsiella pneumoniae* and members of the *Proteus*, *Enterobacter* and *Citrobacter* species are common bacteria isolated during secondary infections [12-15]. Secondary infections, such as nosocomial or hospital-acquired illnesses, can also be contracted from the patient's surroundings. Due to growing antibiotic use and decades of overuse and misuse, nosocomial microorganisms are frequently resistant to a variety of medicines, which leads to the selection of multi-drug resistant pathogens (MDR pathogens). Over 50,000 people worldwide contract MDR each year, and in about 25% of these instances, no effective antibiotic is available because many significant pharmaceutical companies have stopped looking for novel chemical antimicrobials. *Methicillin-resistant S. aureus* (MRSA), drug-resistant *Streptococcus*, *Vancomycin-resistant Enterococci* (VRE), drug-resistant *Mycobacterium*, *Carbapenem-resistant Enterobacteriaceae* (CRE), *Colistin-resistant Klebsiella*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are examples of organisms that are resistant to antibiotics. Antibiotics were not as widely accessible as they are today, and it is believed that the inability to treat secondary bacterial sepsis contributed to the high reported death rate. During an *influenza pandemic*, *S. pneumoniae*, *H. influenzae*, *S. aureus* and group A *Streptococcus* are the most significant bacterial co-infections. However, among 30 hospitalized patients with laboratory-confirmed infections in California and 10 intensive-care patients in Michigan, two early studies of severe cases of 2009 pandemic influenza A (H1N1) revealed no indication of bacterial pneumonia. These reports may have contributed to the belief that bacterial co-infections contributed little or nothing to the 2009 pandemic influenza fatalities [16-20].

The main purpose of this manuscript, presented in the season, is to briefly analyze the relevance of combating secondary bacteriological infection against the background of viral infection based on the authoritative work carried out.

Search methodology and selection standards. Using various combinations of the phrases "virus," "induced," "bacteria," "pathogenesis," "prevention," "vaccine," and "children," a search of the PubMed database and Google was conducted. We also looked for further publications in the indicated articles' references. After that, we looked over abstracts and titles and included research that were pertinent to the subject at hand. Lastly, only human disease research published in English and Spanish between 1918 and the end of 2014 were included in the search. ***Epithelium of the airways.*** A layer of mucus that serves as a

barrier often covers the epithelium. The primary constituents of mucus are charged glycoproteins called mucins. The most prevalent mucins in human sputum, MUC5AC and MUC5B, have antiviral and anti-inflammatory qualities that support the innate immune system. They also aid in the capture and removal of viruses, although an excess of those mucins may have the opposite effect [1-5]. In addition to acting as a physical barrier, the airway epithelium uses pattern recognition receptors such retinoic acid-inducible gene (RIG)-like helicases, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), and toll-like receptors (TLRs) to identify microorganisms. The innate immune system uses TLRs, which are solitary, noncatalytic, membrane-spanning receptor proteins. TLR lanes and respiratory viruses work together to increase the amount of bacteria in the lungs. NLRs and RIG-like helicases, on the other hand, use cytosolic detection of bacterial and viral components to trigger innate immune responses. Molecules produced during the synthesis and/or breakdown of bacterial peptidoglycan stimulate Nod1 and Nod2, members of the NLR family. Furthermore, the conventional antiviral interferons (INFs), particularly IFN- α and IFN- β , are expressed by a large number of epithelial cells. Additionally, inflammatory cells from the circulation, such as natural killer cells, neutrophils, macrophages, and eosinophils, are drawn to the infected location by the respiratory virus-infected epithelia. Lastly, a variety of molecules, such as platelet-activating factor receptor (PAF-r), carcinoembryonic antigen-related cellular adhesion 1 (CEACAM-1), and intercellular adhesion molecule 1 (ICAM-1), make up the airway epithelium. Viruses can alter these receptors, increasing the likelihood of bacterial adherence. For instance, rhinovirus increases PAF-r expression, which causes *S. pneumoniae* to bind to bronchial epithelial cells [11-18].

Pathophysiology of a secondary bacterial infection that is overlaid. The compromised host defense of the respiratory tract against bacteria after viral infection may be caused by a variety of ways. Studies of successive infections by respiratory viruses and other bacterial pathogens in animal models have led to the extrapolation of several pathways. ***The virus damages the host's epithelial cells.*** During a viral infection, mammalian cells are vulnerable to bacterial adhesion. Viruses can weaken the mucociliary clearance structure, which increases bacterial attachment to mucins and colonization. Additionally, the condensed mucus will prevent immune cells and antimicrobial substances from penetrating. Ciliated cells can be harmed by viruses such as the respiratory syncytial virus (RSV), which can lead to ciliostasis and a decline in mucociliary clearance. The same idea holds true for an influenza virus infection, which results in reduced tracheal mucociliary velocity and *S. pneumoniae* clearance [4-10]. Additionally, virus-induced cell death exhibits inexperienced receptors for bacterial adherence and hinders the mechanical removal of the attached pathogens. Research has demonstrated that the RSV virus causes *Haemophilus influenza*, *Pseudomonas aeruginosa* and *S. pneumoniae* to adhere to airway epithelial cells. Furthermore, rhinovirus and adenovirus both contribute to *S. pneumoniae*'s adherence to airway epithelial cells; however, the measles virus reduces the probability of streptococcal bacteria adhering, suggesting that each virus has a unique mechanism for altering the host cell membrane. Furthermore, the overexpression of surface receptors, such as PAF-r, which is involved in pneumococcal invasion, may potentially contribute to bacterial adherence. Bacterial adhesion creates a biofilm in cystic fibrosis patients, causing *P. aeruginosa* to permanently colonize their airways. Pneumococcal biofilm growth on the lining of the airways is also caused by viruses like influenza, rhinovirus, and RSV. Additionally, RSV raises the possibility that *Bordetella pertussis* and *Staphylococcus aureus* will cling to Hep-2 (human epidermoid carcinoma) epithelial cells [18-21].

The impact of viruses on the immune system. One potential cause of the widespread subsequent bacterial pneumonia linked to viral infection is post-viral persistent desensitization of lung sentinel cells to TLR signals. For example, after influenza virus infection, TLR4 and TLR5 pathways are changed, which reduces neutrophil attraction and increases *S. pneumonia* and *P. aeruginosa* attachment to the airway epithelial cells. Proinflammatory molecules are produced as part of the immune responses triggered by the interaction between host cells and pathogens during an infection. Proinflammatory cytokines like TNF- α that are released in response to infection may be harmful to the host cells even if they play an essential role as antibacterial agents. Type I IFNs are produced when TLR and RIG-I-like receptors are activated during a viral infection. These IFNs can increase the inflammatory response to

TLR ligands, such as lipopolysaccharide (LPS). Furthermore, after a respiratory virus infection, some bacteria, including *S. aureus*, integrate into the A549 respiratory epithelial cells (adeno-carcinomic human-alveolar basal-epithelial cells) by upregulating ICAM-1 expression.⁵⁴ RSV is different from influenza virus in that it causes bacterial infection by upregulating cellular receptors such as CEACAM-1 and ICAM-1. Lastly, bacterial identification results from the interaction between type I IFNs and Nod1/Nod2 signaling, which also indicates detrimental effects in the virally infected host [7-14].

Antimicrobial susceptibility tests revealed that MDR *Acinetobacter baumannii* had a high level of resistance. Of these strains, 87.5% were susceptible to amikacin, 19% to colistin, and 1% to trimethoprim/sulfamethoxazole. All other tested medicines, including imipenem and meropenem, were ineffective against MDR *A. baumannii* strains. Three (30%) of the *Klebsiella pneumoniae* ESBL, CPE strains were susceptible to trimethoprim sulfamethoxazole, while three (30%) were susceptible to colistin. Gentamycin and colistin were effective against all strains of *Klebsiella pneumoniae* CPE. One strain of *Klebsiella pneumoniae* without CPE or ESBL and CPE was discovered. Trimethoprim/sulfamethoxazole was effective against all four strains of *Stenotrophomonas maltophilia*. *Providencia stuartii* was resistant to every antibiotic tested; however, because of its inherent resistance to colistin and imipenem, it was not examined. Trimethoprim/sulfamethoxazole was effective against all four strains of *Stenotrophomonas maltophilia*. *Providencia stuartii* was resistant to every antibiotic that was tested; however, it was not tested against imipenem because of its inherent low activity on this species and colistin because of its inherent resistance [7-12]. Before the blood culture results were known, the patient passed away. Ceftazidime, piperacillin/tazobactam, and amikacin were effective against *Pseudomonas aeruginosa* strains. One strain (7.1%) of *Enterococcus* was resistant to vancomycin; the other strains were susceptible to linezolid, teicoplanin, and vancomycin. Despite the fact that *Staphylococcus aureus* MRSA is a prevalent secondary infection agent, we were only able to identify three isolates that were sensitive to teicoplanin, vancomycin, and linezolid. During the six months of this trial, 205 out of 243 patients in the COVID-19 Medical Support Unit Tirgu Mures died from COVID-19 and decompensation of underlying illnesses, resulting in an 84.4% mortality rate. Regardless of the kind of secondary infection (fungal or bacterial) or the site of infection, mortality was even higher in patients with secondary bacterial infection (93%, OR = 3.11, CI 95%: 1.04–12.60). At the conclusion of this trial, 4 out of 59 patients with subsequent bacterial infections had survived [13-21].

Discussion. A significant side effect of the 2009 influenza pandemic was secondary bacterial infection, which was present in nearly 1 in 4 severe or fatal cases, though at varied rates. Adults, intensive care unit patients, and those who died seemed to have greater incidence of bacterial infection, which was linked to morbidity and death. The most frequent bacteria found were *Streptococcus pneumoniae*, and ventilator-associated pneumonia with species such *Acinetobacter baumannii*, *Achromobacter xylosoxidans*, *methicillin-resistant Staphylococcus aureus* and *Escherichia coli* was widespread in ICU patients. Studies of hospitalized patients who did not need an intensive care unit and those of pediatric hospitalized patients showed a decreased rate of bacterial co-infection, however the latter was very variable. Although the 2009 pandemic's overall morbidity and mortality varied by nation, it was compared to a severe seasonal influenza outbreak [1,3,4,5]. Nonetheless, there were two significant variations in the 2009 pandemic's epidemiologic pattern: first, a low average age of death in fatal cases (53 years as opposed to 83 years during seasonal influenza) and high rates of intensive care unit (ICU) occupancy. A UK study revealed a "w" shaped morbidity curve with a peak in young people, and these two characteristics point to a serious population impact. Although the 1918 pandemic has been used as a model for pandemic planning, the availability of antibiotics, critical care, and extra-corporeal membrane oxygenation (ECMO) have significantly increased survival during a modern pandemic, making it unlikely that the 1918 case fatality rates would recur in the present day. ECMO use increased dramatically in 2009 and is linked to excellent survival rates. Furthermore, since treatment and prevention methods are also accessible for bacterial infections, it is crucial to measure the relative contribution of direct viral effects compared to bacterial secondary infections in order to comprehend the morbidity and mortality impact of a modern pandemic. The majority of the studies we evaluated for this evaluation ignored the significance

of testing for bacterial complications during an influenza pandemic. Both seasonal and pandemic influenza require active surveillance and mechanisms for quick evaluation of secondary bacterial morbidity and death should be in place for the best possible response and mitigation of avoidable morbidity and mortality [6-11]. During a pandemic, secondary bacterial infection diagnosis and treatment should always be taken into consideration. There is currently little information available regarding bacterial coinfection during the 1918 influenza pandemic. When Morens et al. examined autopsy data from 58 lung tissue samples taken during the 1918 influenza pandemic, they discovered that nearly every sample had histologic evidence of severe bacterial pneumonia. Additionally, the authors searched the literature for autopsy case series and analyzed data from 68 high-quality autopsy case series involving 3074 participants. This demonstrated that at least one bacterium was found in almost 92% of autopsy lung cultures. More than ten sterile-site antemortem cultures from people with pneumonia during the 1918 pandemic were reported in a different investigation by Chien et al. This is the first systematic review that we are aware of that estimates the prevalence of secondary bacterial infections and pneumonia during pandemic influenza A (H1N1)pdm09. We determined the rates of bacterial coinfection independently for hospitalized cases with confirmed pneumonia, hospitalized cases admitted to the intensive care unit, hospitalized cases admitted to general wards, and pediatric hospitalized cases. The results indicated that the risk of bacterial infection was highest for both ICU-admitted and fatal cases [16-21].

Conclusions. Even during a pandemic, medical professionals must pay special attention to the occurrence of secondary bacterial infections linked to medical care. Multidrug-resistant organisms frequently caused nosocomial infections in our group, which were linked to a high death rate. The geographic specificities of co-infections and secondary infections in critically ill COVID-19 patients are highlighted in this study. Even in recently established institutions, co-infections and secondary infections occurred, and tiny geographic areas experienced unique difficulties in managing the disease, despite COVID-19 being a well-characterized and well researched pathology.

Few studies of the 2009 influenza pandemic, we discovered, addressed bacterial complications and testing. Nearly one in four patients in the trials that did report on this had a secondary bacterial infection, with *Streptococcus pneumoniae* being the most often found pathogen. Serious consequences like death and intensive care unit hospitalization were linked to bacterial problems. Improved routine pneumococcal vaccination uptake in people with an indication may lessen the burden of a pandemic, and prevention and treatment of bacterial secondary infection should be a key component of pandemic planning.

There is a noticeable correlation between major bacterial infections and viral illnesses. The prevention and treatment of viral diseases, particularly in young children, require a similar focus. Additionally, medical professionals should stress to parents the significance of clinical follow-up for newborns and young children with VRTI diagnoses. Furthermore, the use of MxA in the diagnosis of pediatric viral diseases seems encouraging.

References.

1. Hendaus MA, Jomha FA, Alhammadi AH. Virus-induced secondary bacterial infection: a concise review. *Ther Clin Risk Manag*. 2015 Aug 24;11:1265-71. doi: 10.2147/TCRM.S87789.
2. Manohar P, Loh B, Nachimuthu R, Hua X, Welburn SC and Leptihn S (2020) Secondary Bacterial Infections in Patients With Viral Pneumonia. *Front. Med*. 7:420. doi: 10.3389/fmed.2020.00420
3. Bradley BT, Bryan A. Emerging respiratory Infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. *Semin Diagn Pathol*. (2019) 36:152–9. doi: 10.1053/j.semdp.2019.04.006
4. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. *Front Microbiol*. (2017) 8:1041. doi: 10.3389/fmicb.2017.01041

5. Wang H, Anthony D, Selemidis S, Vlahos R, Bozinovski S. Resolving viral-induced secondary bacterial infection in COPD: a concise review. *Front Immunol.* (2018) 9:2345. doi: 10.3389/fimmu.2018.02345
6. Nyangacha RM, Odongo D, Oyieke F, Ochwoto M, Korir R, Ngetich RK, et al. Secondary bacterial infections and antibiotic resistance among tungiasis patients in Western, Kenya. *PLoS Neglect Trop D.* (2017) 11:e0005901. doi: 10.1371/journal.pntd.0005901
7. Kumar A, Chordia N. Bacterial resistance against antibiotics. In: Arora G, Sajid A, Kalia VC, editors. *Drug Resistance in Bacteria, Fungi, Malaria, and Cancer.* Cham: Springer (2017). p. 171–92.
8. Loh B, Leptihn S. A call for a multidisciplinary future of phage therapy to combat multi-drug resistant bacterial infections. *Infect Microb Dis.* (2020) 2:1–2. doi: 10.1097/IM9.0000000000000018
9. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J.* (2020) 55:2000524. doi: 10.1183/13993003.00524-2020
10. Wang J, Tang Y, Ma Y, Zhou Q, Li W, Baskota M, et al. Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review. *Ann Transl Med.* (2020) 8:619. doi: 10.21037/atm-20-3300
11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
12. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* (2020) 8:P475–81. doi: 10.1016/S2213-2600(20)30079-5
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* (2020) 323:1061–9. doi: 10.1001/jama.2020.1585
15. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med.* (2020) 382:929–36. doi: 10.1056/NEJMoa2001191
16. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032
17. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* (2020) 3:1–3. doi: 10.1007/s00134-020-06028-z
18. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med.* (2020) 180:1–11. doi: 10.1001/jamainternmed.2020.0994
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
20. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. *Clin Infect Dis.* (2020) 29:ciaa199. doi: 10.1093/cid/ciaa199

21. MacIntyre, C.R., Chughtai, A.A., Barnes, M. et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis 18, 637 (2018). <https://doi.org/10.1186/s12879-018-3548-0>